SCHEMBL6725587

SCHEMBL6725587

O=S(=O)(Nc1cccc(C2=NCCc3cc(Cl)ccc32)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
IDH2 P48735 1/20 0.46
KDM1A O60341 2/20 0.45
KMT2A Q03164 2/20 0.44
PTPN2 P17706 2/20 0.44
PTPN1 P18031 2/20 0.44
PTPN5 P54829 2/20 0.44
CDK1 P06493 2/20 0.43
CCNB1 P14635 2/20 0.43
CCNA2 P20248 2/20 0.43
CDK2 P24941 2/20 0.43
CDK7 P50613 2/20 0.43
CCNH P51946 2/20 0.43
CCNA1 P78396 2/20 0.43
CCND1 P24385 1/20 0.43
CDK6 Q00534 1/20 0.43
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
PIK3CB P42338 1/20 0.43
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720500 0.92 TSHR (0.50) TSHRKMT2APTPN2PTPN1PTPN5
SCHEMBL6717978 0.92 THRB (0.49) TSHRIDH2KDM1AKMT2APTPN2
SCHEMBL6720398 0.90 TSHR (0.47) TSHRIDH2KMT2APTPN2PTPN1
SCHEMBL6714887 0.89 TSHR (0.50) TSHRKMT2APTPN2PTPN1PTPN5
SCHEMBL6720522 0.88 CDK1 (0.47) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL6779986 0.86 CYP19A1 (0.43) KMT2APKMLMNATHRBMEN1
SCHEMBL6715167 0.85 PKM (0.46) TSHRIDH2KMT2ACDK1CCNB1
SCHEMBL7124579 0.85 KDM1A (0.48) TSHRIDH2KDM1AKMT2APTPN2
SCHEMBL6720458 0.84 UQCRB (0.47) HSD17B2LMNAGAA
SCHEMBL6718324 0.84 TSHR (0.47) TSHRIDH2KMT2APTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A TSHR 3790/4885IDH2 356/4885KDM1A 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.